– May 21-23, 2026 | Warsaw, Poland – Zy Therapeutics will be attending the International Conference on Tuberous Sclerosis Complex and Related Neurocutaneous Disorders in Warsaw, where the team will…
Zy Therapeutics is pleased to announce its participation in the American Academy of Neurology (AAN) Annual Meeting 2026 in Chicago, one of the leading global forums for advances in neurological…
Zy Therapeutics is pleased to announce its participation in the International Conference on Tuberous Sclerosis Complex and Related Neurocutaneous Disorders, taking place May 21–23, 2026 in Warsaw, Poland. This meeting…
– April 18-22, 2026 | Chicago – Zy Therapeutics will be attending the American Academy of Neurology (AAN) Annual Meeting 2026 in Chicago, where the team will continue engaging with…
- December 5-9, 2025 | Atlanta - Zy Therapeutics will be attending AES 2025 in Atlanta, Georgia, where the team will highlight ongoing work toward developing a disease-modifying treatment for…
As Zy Therapeutics prepares for the 2025 American Epilepsy Society (AES) Annual Meeting, the company is placing a strong emphasis on building the strategic relationships needed to advance its rare-epilepsy…
Zy Therapeutics is gearing up for an important presence at the 2025 American Epilepsy Society (AES) Annual Meeting, where the company will highlight meaningful progress on Kamini® (ZY-001)—its lead investigational…
Zy Therapeutics will convene its 2025 Scientific Advisory Board (SAB) meeting during the American Epilepsy Society (AES) Annual Meeting on Friday, December 5, 2025, in Atlanta, Georgia. This Scientific Advisory…
- September 18–20, 2025 | Madison, WI - Zy Therapeutics is pleased to announce that our Chief Medical & Scientific Officer, Dr. Jeffrey Loeb, will be attending the Sturge-Weber Foundation…
Brain calcification is more than a radiographic finding, it’s a devastating driver of seizures, migraines, and cognitive decline in rare CNS diseases like Sturge-Weber Syndrome and Tuberous Sclerosis. At ZY…